Xiaoyun Li - Researcher Profile | RDL Research Database

Publications

3 shown

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas , Igor Puzanov , Reinhard Dummer +33 more

2015 The Lancet Oncology 1528 citations

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid , Caroline Robert , Adil Daud +23 more

In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rat...

2013 New England Journal of Medicine 3352 citations

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert , Antoni Ribas , Jedd D. Wolchok +22 more

2014 The Lancet 1743 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 6,623
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-5644-846X

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.